BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib

Bibliographic Details
Main Authors:	Ranzani, Marco, Alifrangis, Constantine, Perna, Daniele, Dutton-Regester, Ken, Pritchard, Antonia, Wong, Kim, Rashid, Mamunur, Robles-Espinoza, Carla Daniela, Hayward, Nicholas K, McDermott, Ultan, Garnett, Mathew, Adams, David J
Format:	Online
Language:	English
Published:	BlackWell Publishing Ltd 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296225/

Similar Items

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
by: Homet Moreno, Blanca, et al.
Published: (2015)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
by: Joshi, Monika, et al.
Published: (2015)

The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response?
by: Garnett, Mathew J, et al.
Published: (2014)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
by: Vujic, Igor, et al.
Published: (2014)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
by: Tschandl, Philipp, et al.
Published: (2013)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
by: Colombino, Maria, et al.
Published: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
by: Chiappetta, Caterina, et al.
Published: (2015)

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
by: King, Alastair J., et al.
Published: (2013)

Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)

Trametinib: a MEK inhibitor for management of metastatic melanoma
by: Lugowska, Iwona, et al.
Published: (2015)

Targeting the RB-E2F pathway in breast cancer
by: Johnson, Jackie, et al.
Published: (2016)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
by: Zebary, A, et al.
Published: (2013)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
by: Birkeland, Einar, et al.
Published: (2013)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
by: Takahashi, Naoki, et al.
Published: (2014)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
by: Shackelford, Rodney, et al.
Published: (2014)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
by: Negru, Serban, et al.
Published: (2014)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
by: Kriegsmann, Mark, et al.
Published: (2015)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
by: Palomba, Grazia, et al.
Published: (2016)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
by: Módos, Orsolya, et al.
Published: (2016)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
by: Hsu, Hung-Chih, et al.
Published: (2016)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
by: Lionetti, Marta, et al.
Published: (2015)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
by: Mangana, Joanna, et al.
Published: (2015)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
by: Chang-Hao Tsao, Simon, et al.
Published: (2015)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
by: Wong, Deborah JL, et al.
Published: (2015)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
by: Manca, Antonella, et al.
Published: (2015)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
by: Wong, Deborah JL, et al.
Published: (2014)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
by: Carlino, M S, et al.
Published: (2014)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
by: Williams, Casey B, et al.
Published: (2015)

NRAS mutant melanoma – undrugable?
by: Posch, Christian, et al.
Published: (2013)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
by: Luke, Jason J, et al.
Published: (2014)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
by: BALL, DOUGLAS W., et al.
Published: (2015)

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter
by: Qiu, Jian-Ge, et al.
Published: (2015)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
by: Draganova, Dafina, et al.
Published: (2015)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
by: Minor, David R., et al.
Published: (2015)

Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties
by: Menden, Michael P., et al.
Published: (2013)

Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy
by: Knijnenburg, Theo A., et al.
Published: (2016)

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen
by: Lynch, James T., et al.
Published: (2016)

Deregulated Nras Expression in Knock-In Animals Harboring a Gammaretroviral Long Terminal Repeat at the Nras/Csde1 Locus
by: Ballarín-González, Borja, et al.
Published: (2013)

Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
by: Shen, Yinchen, et al.
Published: (2013)